- Study at RCSI
- Schools, Faculties, Departments
- Faculty of Medicine & Health Sciences
- School of Medicine
- School of Pharmacy
- School of Physiotherapy
- School of Postgraduate Studies
- School of Nursing & Midwifery
- Academic Departments
- Institute of Leadership
- Health Professions Education Centre (HPEC)
- Simulation
- Student, Academic & Regulatory Affairs
- CoMPPAS
- Faculty of Sports and Exercise Medicine
- Faculty of Nursing & Midwifery
- Faculty of Dentistry
- Faculty of Radiologists
- Alumni
- Surgical Affairs
- Research & Innovation
- Innovation
- Strategic Academic Recruitment Programme
- Research News & Events
- Research Areas
- Principal Investigators
- Research Networks & Centres
- Technology Cores & Research Facilities
- Research Office
- Employment Opportunities
- PhD Projects and Postgraduate Training Opportunities
- Research Ethics
- Technology Transfer Office & Management of Intellectual Property
- Research by Faculty
- Research by Academic Department
- Research by School
- Human Resources Strategy for Researchers (HRS4R)
- About RCSI
- Council
- CEO and Senior Management
- History
- Contact us and location
- RCSI Strategic Plan 2018 - 2022
- Publications
- Communications
- Venue hire
- 26 York Street
- Equality Diversity and Inclusion
- Athena SWAN
- RCSI and the wider community
- Quality Enhancement Office
- Academic Health Centre
- Irish Society of Urology
- Freedom of Information (FOI)
- Eduroam
- Green Campus
- RCSI Collaborate
- RCSI International
Commercialisation
One of the key remits of the Centre is to increase commercialisation opportunities of research outputs. To this end we work closely with the RCSI Technology Transfer Office in the following areas:
Motoneuron degeneration
Commercialisation activities on research into treatment for motoneuron degeneration is funded through two main awards:
- EI Technology Development Award - Systemic delivery of angiogenin protein for the treatment of ALS: Therapeutic modulation of angiogenin levels in the spinal cord
- SFI Technology and Innovation Development Award, Feasibility - Systematic administration of amiloride for the treatment of motoneuron disorders
Alzheimer's Disease
- Pfizer Medivation - Study to explore the mechanism of action of Dimebon in AD and other neurodegenerative disorder (focusing on cellular bioenergetics)
- H. Lundbeck A/S
Multiplexing and work flow solutions
- Research in collaboration with Luxcel aims to extend of the range of applications of the current Mitoxpress reagent, assist with development and validation of new Luxcel probes and the development of multiplexing and work flow solutions.
Epilepsy
Commercialisation activities on research into treatment for epilepsy include:
- SFI Technology and Innovation Development Award, Feasability - Antagomirs for the treatment of epilepsy.
- The team also holds intellectual property / patent protection around miRNA based inhibitors for epilepsy and P2X7 reveptors as targets for status epilepticus.